Letter from a Brazilian Supporter to Geraldine Ferraro

Letter from a Brazilian supporter to Geraldine Ferraro.https://ir.lawnet.fordham.edu/vice_presidential_campaign_correspondence_1984_international/1257/thumbnail.jp

Učinak intraartikularne plazme obogaćene trombocitima, biofizički aktivirane autologne plazme obogaćene trombocitima (PRP-a) i primjene mezenhimnih matičnih stanica na interleukine u pasa s osteoartritisom

The aim of this study was to determine the levels of cytokines (TNF-α, PGE2, IL-1β, IL-6, IL-10) in synovial fluid samples from joints affected by osteoarthritis (OA), and to assess the efficacy of a single intraarticular (IA) injection of an autologous platelet rich plasma (PRP), mesenchymal stem cells (MSCs), bio-physically activated platelet rich plasma (B-PRP) and their combinations for treatment of OA in dogs. Thirty-six different breeds, gender, age and weight dogs affected by OA were used as materials. The groups were divided into: PRP, MSCs, PRP + MSCs, B-PRP, B-PRP + MSCs and SC (Saline Control). Only one dose was injected. The primary inclusion criterion for the dogs was that they had no systemic disease. The Genesis Cell System was used for preparation of autologous PRP, and the platelets were counted before injection. The Genesis Autologous Cell System 2 (30ml) was used as the bio-physical activator in preparation of the PRP. The bio-PRP physical activator device was mounted on one end and the other end of the activator was left empty. Biovalda Health Technology Inc. was used for producing allogeneic adipose stem cells. Cytokines (TNF-α, PGE2, IL-1β, IL-6, IL-10) in terms of quantities were measured using enzyme-linked immunosorbent assay (ELISA) from the synovial fluid samples before treatment and on the 0, 15th, 30th, 60th and 90th days of treatment. In all cases, clinic and radiographic examinations were performed on the 0, 15th, 30th, 60th and 90th days. The results obtained from the PRP + MSCs combination group were more successful compared to the other groups. It was noted that successful results could be obtained with PRP alone or in combination with stem cells, especially if repeated intra-articular injections are required. Also future studies are needed to understand the effectiveness of B-PRP. Only the B-PRP and MSCs combination were effective on many enzymes, but varying results were obtained in all cases.Cilj istraživanja bio je odrediti razine citokina TNF-α, PGE2, IL-1β, IL-6 i IL-10 u uzorcima sinovijske tekućine iz zglobova zahvaćenih osteoartritisom (OA) te procijeniti učinkovitost pojedinačne intraartikularne injekcije (IA) (PRP), mezenhimnih matičnih stanica (MSC), biofizički aktivirane plazme obogaćene trombocitima (B-PRP) i njihovih kombinacija u liječenju osteoartritisa u pasa. U istraživanju je upotrijebljeno 36 pasa s osteoartritisom, različitih pasmina, spola, dobi i tjelesne mase. Oni su podijeljeni u skupine PRP, MSCs, PRP + MSCs, B-PRP, B-PRP + MSCs i SC (Saline Control). Injicirana je samo jedna doza. Primarni je kriterij za uključivanje pasa bio da nisu imali sistemsku bolest. Autologni stanični sustav Genesis 2 (30 mL) upotrijebljen je kao biofizički aktivator u pripremi PRP-a. Uređaj za biofizičko aktiviranje PRP-a montiran je na jednom kraju, a drugi je kraj aktivatora ostao prazan. Alogene adipozne matične stanice proizvedene su prema uputama a Biovalda Health Technology Inc. Količina citokina TNF-α, PGE2, IL-1β, IL-6 i IL-10 dobivena je testom ELISA iz uzoraka sinovijalne tekućine prije liječenja te 0., 15., 30., 60. i 90. dan liječenja. U svim su slučajevima klinički i radiološki pregledi obavljeni 0., 15., 30., 60. i 90. dan. Rezultati dobiveni u skupini PRP + MSC pokazali su veću učinkovitost u usporedbi s drugim skupinama. Zapaženo je da se dobri rezultati mogu postići samo uz PRP ili u kombinaciji PRP-a i matičnih stanica, posebno u slučaju ponovljene intraartikularne injekcije. Potrebna su i daljnja istraživanja kako bi se objasnila učinkovitost B-PRP-a. Vezano za enzime, samo je kombinacija B-PRP-a i MSC-a bila učinkovita, ali s različitim rezultatima

Rezultati endoskopski asistirane gastropeksije kod pasa

The aim of this study was to investigate the use of endoscopy jointly with gastropexy in dogs as a potential mean to aid prevention and evaluation of the long-term efficiency of this procedure for gastric dilatation-volvulus. The study was performed on ten healthy adult medium- and large-breed dogs. The dogs had no abnormal fi nding upon physical examination and each underwent an endoscopically assisted gastropexy procedure. After surgery all dogs were in good condition. The surgical procedure was followed by x-ray and ultrasonographic examinations. The records included data for gastropexy anatomic location and length, duration of the surgical procedure and complications. The mean ± SD gastropexy length was 3.0 ± 0.25 cm, as determined by ultrasonography, and the mean duration of the surgical procedure was 20 ± 5 minutes. It appears that endoscopically assisted gastropexy is a simple, fast, safe, and reliable method of performing a prophylactic gastropexy in dogs. This procedure maximizes the benefi ts of decreased morbidity and shorter duration of anaesthesia associated with minimally invasive surgeryCilj studije je bio da se ispita istovremena upotreba endoskopije sa gastropeksijom kod pasa, kao potencijalno podesna metoda za prevenciju i evaluaciju gastričke dilatacijevolvulusa, kao i efi kasnost duže primene ove tehnike. Ispitivanje je obavljeno na 10 zdravih, odraslih pasa, srednjih i velikih rasa. Svaki pas je podvrgnut endoskopiji zajedno sa procedurom gastropeksije. Obavljeni su radiografski pregledi kao i pregledi ultrazvukom i sve životinje su bile dobrog zdravstvenog stanja. Podaci koji su dobijeni, odnosili su se na anatomsku lokaciju gastropeksije, dužinu trajanja hirurške procedure kao i moguće komplikacije. Srednja vrednost (±SD) dužine gastropeksije, dobijena ultrazvučnim pregledom je bila 3,0 ± 0,25 cm, a srednja vrednost dužine trajanja hirurške procedure je bila 20 ± 5 minuta. Na osnovu rezultata, može se pretpostaviti da je endoskopski asistirana gastropeksija jednostavna, brza, bezbedna i pouzdana metoda prilikom profi laktičke gastropeksije kod pasa. Ovom metodom smanjuje se morbiditet, kratko traje anestezija, uz maksimalnu redukciju invazivne hirurške metode

Rezultati endoskopski asistirane gastropeksije kod pasa

The aim of this study was to investigate the use of endoscopy jointly with gastropexy in dogs as a potential mean to aid prevention and evaluation of the long-term efficiency of this procedure for gastric dilatation-volvulus. The study was performed on ten healthy adult medium- and large-breed dogs. The dogs had no abnormal fi nding upon physical examination and each underwent an endoscopically assisted gastropexy procedure. After surgery all dogs were in good condition. The surgical procedure was followed by x-ray and ultrasonographic examinations. The records included data for gastropexy anatomic location and length, duration of the surgical procedure and complications. The mean ± SD gastropexy length was 3.0 ± 0.25 cm, as determined by ultrasonography, and the mean duration of the surgical procedure was 20 ± 5 minutes. It appears that endoscopically assisted gastropexy is a simple, fast, safe, and reliable method of performing a prophylactic gastropexy in dogs. This procedure maximizes the benefi ts of decreased morbidity and shorter duration of anaesthesia associated with minimally invasive surgeryCilj studije je bio da se ispita istovremena upotreba endoskopije sa gastropeksijom kod pasa, kao potencijalno podesna metoda za prevenciju i evaluaciju gastričke dilatacijevolvulusa, kao i efi kasnost duže primene ove tehnike. Ispitivanje je obavljeno na 10 zdravih, odraslih pasa, srednjih i velikih rasa. Svaki pas je podvrgnut endoskopiji zajedno sa procedurom gastropeksije. Obavljeni su radiografski pregledi kao i pregledi ultrazvukom i sve životinje su bile dobrog zdravstvenog stanja. Podaci koji su dobijeni, odnosili su se na anatomsku lokaciju gastropeksije, dužinu trajanja hirurške procedure kao i moguće komplikacije. Srednja vrednost (±SD) dužine gastropeksije, dobijena ultrazvučnim pregledom je bila 3,0 ± 0,25 cm, a srednja vrednost dužine trajanja hirurške procedure je bila 20 ± 5 minuta. Na osnovu rezultata, može se pretpostaviti da je endoskopski asistirana gastropeksija jednostavna, brza, bezbedna i pouzdana metoda prilikom profi laktičke gastropeksije kod pasa. Ovom metodom smanjuje se morbiditet, kratko traje anestezija, uz maksimalnu redukciju invazivne hirurške metode

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks